Sinopep

Sinopep-Allsino Bio Pharmaceutical Co., Ltd. is a biopharmaceutical enterprise focusing on peptide drugs and small-molecule chemical drugs, combining independent R&D with customized R&D services. As a national high-tech enterprise and a provincial-level science and technology enterprise, the company was established in April 2009 and is located in the Lianyungang Economic and Technological Development Zone at the national level. On May 20, 2021, the company was listed on the STAR Market of the Shanghai Stock Exchange (Stock Abbreviation: Sinopep; Code: 688076) and currently employs over 900 people. Committed to technological innovation, the company aims to break through technical bottlenecks in drug R&D and production, building a full industrial chain from advanced pharmaceutical intermediates and active pharmaceutical ingredients (APIs) to finished dosage forms. It provides global partners with green, low-cost, high-quality, and efficient pharmaceutical products and technical services.In terms of R&D, the company adheres to technological innovation as its driving force, continuously strengthening its independent innovation capabilities. For three consecutive years, it has invested more than 10% of its total annual revenue in R&D expenses. The company operates three provincial-level R&D centers: Sinopep, Allsino, and Xinbosi. It has assembled an internationally competitive R&D team led by experts from national key talent introduction programs and provincial talent plans. The team currently consists of over 160 R&D personnel, including more than 40 individuals with master's or doctoral degrees and six returnees from overseas. By integrating hardware and software resources, the R&D centers achieve technological convergence, providing solid technical support for the company’s full-industry-chain business layout. Furthermore, the company has established a Nobel Prize Workstation in collaboration with Professor Hartmut Michel, a German biochemist and Nobel Laureate in Chemistry, to accelerate technological innovation. The company holds 77 authorized patents, including 36 invention patents, and has established robust industry-academia-research collaborations with numerous universities and research institutes.In terms of production, the company has established two modern manufacturing bases in Lianyungang, Jiangsu Province, and Jiande, Zhejiang Province. These facilities possess large-scale production capabilities covering both peptides and small-molecule chemical drugs, complying with international regulatory standards and spanning the entire industrial chain from "advanced pharmaceutical intermediates to APIs and finished dosage forms." The company’s hard capsules, tablets, lyophilized powder injections, small-volume injections, and certain APIs have passed the National Good Manufacturing Practice (GMP) certification. Its peptide API quality system successfully passed the U.S. FDA cGMP on-site inspections three times, in 2014, 2016, and 2019. Notably, during the re-inspection in January 2019, the company passed with "zero defects" ("NAI"), laying a foundation for enhancing the international competitiveness of its products.Regarding market strategy, the company adheres to an internationalization strategy. Through global product and business layouts, talent development, and production system construction, its products and technologies have achieved international competitiveness. After years of development, leveraging advanced R&D technologies and a high-standard quality management system, the company has gained recognition from several globally renowned pharmaceutical companies and established long-term, stable partnerships. Looking ahead, the company will pursue innovation-driven growth, continuously intensifying technological innovation. It aims to evolve into an internationally renowned biopharmaceutical enterprise centered on innovative peptide drugs, supported by blockbuster generic drugs and technical services, with comprehensive R&D and production capabilities across the entire pharmaceutical industry chain.